Pharmacogenomics of Statins

Beth N. PeshkinTidbits

Is genetic testing to assess the risk of statin-induced myopathy commercially available?

[Scroll to bottom for answer]























Yes. Commercial testing for SLCO1B1 variants is available. Although variants in this and other genes play a role in statin-myopathy, the clinical utility of such testing is unproven and is not recommended for routine use at the present time.

Stewart, Alison. “SLCO1B1 polymorphisms and statin-induced myopathy.”PLoS currents 5 (2013).

via Beth Peshkin, MS, CGC